Ono Pharma to Present Phase 3 Sapablursen Trial Design at ASH 2026

PUBT · 11h ago
Ono Pharma to Present Phase 3 Sapablursen Trial Design at ASH 2026
  • Ono Pharmaceutical received European Commission orphan medicinal product designation for sapablursen to treat polycythemia vera.
  • Its U.S. subsidiary Deciphera is developing sapablursen in the global, randomized, double-blind, placebo-controlled Phase 3 INTREPID study.
  • The trial’s design will be presented December 13, 2026, at the American Society of Hematology annual meeting in New Orleans.
  • Sapablursen previously received U.S. fast-track, orphan drug and breakthrough therapy designations, with Japanese orphan drug designation granted in September 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.